CRL — Charles River Laboratories price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
Key stats#
Data provided bySource: Twelve DataPrice data
- Price
- $337.52
- YTD price return
- +69.20%
- YTD total return
- +69.20%
- Market cap
- 16.2B
- Enterprise value
- 18.9B
- Shares outstanding
- 47.9M
- 52W low
- $146.20
- 52W high
- $379.63
- From 52W high
- -11.09%
- From 52W low
- +130.86%
- 52W range
- 82%$146–$380
- Beta
- 1.37
Volume
- Rel volume
- 0.90×
- 30D volume
- 1.2M
- 30D $ vol
- 386M
Insider trading
- Insider net 1W
- none
- Insider net 1M
- −$9.2M
- Insider net 3M
- −$31.0M
- Insider net 1Y
- −$52.1M
Form 4 transactions by trade date, as filed; latest on file 2026-10-22.
Fundamentals
- Sales (ttm)
- 4B
- Sales/share
- $82.99
- EPS (ttm)
- $0.83
- FCF (ttm)
- 399.6M
- FCF/share
- $8.34
- Book value/share
- $67.35
- Net margin
- 1.01%
- ROE
- 1.25%
- ROA
- 0.54%
- Debt / equity
- 0.76×
- Current ratio
- 1.41
Growth (CAGR, ttm) · 10Y
- Sales
- -1.17%-1.93%+3.03%+9.75%
- Net income
- n/a-56.22%-36.73%-11.85%
- FCF
- -26.57%+2.75%-2.43%+5.11%
- Shares
- -2.65%-2.25%-1.03%+0.12%
Per-share growth (CAGR, ttm) · 10Y
- EPS
- n/a-55.36%-36.04%-11.99%
- Sales/share
- +1.52%+0.33%+4.10%+9.61%
- FCF/share
- -24.57%+5.12%-1.42%+4.98%
- Book value/share
- -2.68%+1.48%+6.97%+13.89%
- Price
- +97.61%+23.00%-2.10%+17.34%
- Total return
- +97.61%+23.00%-2.10%+17.34%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 407.8×
- P/OI (ttm)
- 101.7×
- Fwd P/E
- 26.5×
- P/S (ttm)
- 4.1×
- P/B (mrq)
- 5.0×
- P/FCF (ttm)
- 40.5×
- EV/EBITDA (fy)
- 42.6×
- EV/Sales (ttm)
- 4.8×
- FCF yield (ttm)
- 2.47%
- Buyback yield (realized, 1y)
- 2.65%
- Shareholder yield (realized, 1y)
- 2.65%
- Buyback yield (cash, ttm)
- 2.00%
- Shareholder yield (cash, ttm)
- 2.00%
Vs own 10Y history
- P/E
- 99th
- P/OI
- 92nd
- P/S
- 86th
- P/B
- 71st
- P/FCF
- 94th
Bar = where today’s multiple sits in CRL’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).
Performance · price returntotal return · as of 2026-11-06#
Data provided bySource: Twelve DataFundamentals#
Operating income
5Y CAGR −43.4%10Y CAGR −19.0%YoY +51.4%EPS (diluted)
5Y n/m10Y n/mYoY +523.6%Free cash flow
5Y CAGR +6.4%10Y CAGR +7.8%YoY +16.3%TTM: operating cash flow $622.4M, capex −$222.8M
Q3 2026: operating cash flow $254.1M, capex −$46.8M
Shares (diluted)
5Y −2.1%10Y +4.1%YoY −1.7%Net income
5Y n/m10Y n/mYoY +512.0%About Charles River Laboratories#
Data provided bySource: Twelve DataCharles River Laboratories International, Inc. is a life sciences company that provides products and services supporting pharmaceutical and biotechnology research, drug discovery, non-clinical development, and safety assessment. Its Research Models and Services business supplies purpose-bred rodents and genetically defined research models, along with related services used in laboratory and preclinical studies. Through Discovery and Safety Assessment, the company conducts regulated and non-regulated in vitro, in vivo, and in silico studies, laboratory support, consulting, and program management for potential medicines. Its Manufacturing Solutions activities include microbial testing and biologics-related services that help address quality, contamination control, and development requirements. Charles River Laboratories International, Inc. serves pharmaceutical and biotechnology companies, government agencies, academic institutions, and other research organizations across international life sciences markets. Its integrated role connects early laboratory research with the testing and development processes required to advance medical products toward regulatory review.
Wilmington, MA·18,300 employees·Diagnostics & Research·criver.com·As of Oct 28, 2026
Recent filings#
- Nov 4Earnings · Earnings release — EPS $3.09 vs $2.98 est. (+3.7%); revenue $982.7M (−2% y/y) 7.3%
- Sep 30Insider buy · Coleman Glenn (EVP & Chief Financial Officer) bought 10 shares for $2,974 at $297.43
- Aug 18Insider sale · Andrews Nancy C (Director) sold 573 shares for $163K at $285.24
- Aug 6Insider sale · Knell Michael Gunnar (SVP, Finance and CAO) sold 6,645 shares for $1.7M at $258.53–$265.17
- Aug 6Insider sale · Creamer Victoria L (EVP & Chief People Officer) sold 4,179 shares for $1.1M at $259.16
ETFs holding CRL#
28 of the 193 ETFs ChartRow carries live hold CRL. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).
| Fund | Name | Filed weight |
|---|---|---|
| IBB | iShares Biotechnology ETF | 0.8% |
| RSP | Invesco S&P 500 Equal Weight ETF | 0.2% |
| VBR | Vanguard Small-Cap Value ETF | 0.2% |
| VHT | Vanguard Health Care ETF | 0.2% |
| XLV | Health Care Select Sector SPDR Fund | 0.2% |
| VB | Vanguard Small-Cap ETF | 0.1% |
| IWS | iShares Russell Mid-Cap Value ETF | 0.1% |
| IWR | iShares Russell Midcap ETF | 0.1% |
Related Healthcare#
Data provided bySource: Twelve Data| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +16.98% | -0.79% |
| JNJ | Johnson & Johnson | +8.42% | +1.43% |
| ABBV | AbbVie Inc. | +9.23% | +1.07% |
| MRK | Merck & Co. Inc. | +3.37% | -0.14% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | +4.74% | -0.40% |
| NVS | Novartis AG | +15.46% | +0.38% |
| TMO | Thermo Fisher Scientific Inc. | +5.81% | +2.63% |
| AMGN | Amgen Inc. | +14.36% | +0.03% |
